> top > docs > PubMed:24691501 > annotations

PubMed:24691501 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T1 18-28 SO:1000009 denotes transition
T4 32-56 D002285 denotes ductal carcinoma in situ
T5 32-56 D002285 denotes ductal carcinoma in situ
T10 69-85 D044584 denotes ductal carcinoma
T11 69-85 D044584 denotes ductal carcinoma
T14 91-97 CVCL_E024 denotes Gemini
T18 98-107 11253 denotes vitamin D
T16 98-107 CHEBI:89324 denotes vitamin D
T17 98-107 D014807 denotes vitamin D
T19 98-107 D014807 denotes vitamin D
T20 98-107 CHEBI:27300 denotes vitamin D
T23 123-140 D002278 denotes carcinoma in situ
T24 123-140 D002278 denotes carcinoma in situ
T26 142-146 CVCL_5552 denotes DCIS
T25 142-146 D002285 denotes DCIS
T27 142-146 D002285 denotes DCIS
T28 180-186 UBERON:0000310 denotes breast
T29 230-246 D044584 denotes ductal carcinoma
T30 230-246 D044584 denotes ductal carcinoma
T33 276-285 GO:0009056 denotes breakdown
T34 293-311 CL:0000185 denotes myoepithelial cell
T35 307-317 UBERON:0000119 denotes cell layer
T39 322-339 UBERON:0005769 denotes basement membrane
T38 322-339 GO:0005604 denotes basement membrane
T44 343-347 CVCL_5552 denotes DCIS
T43 343-347 D002285 denotes DCIS
T45 343-347 D002285 denotes DCIS
T46 407-413 UBERON:0000310 denotes breast
T47 407-420 D001943 denotes breast cancer
T48 407-420 D001943 denotes breast cancer
T51 426-439 CVCL_5552 denotes MCF10DCIS.com
T52 431-435 D002285 denotes DCIS
T54 431-435 D002285 denotes DCIS
T56 436-439 CHEBI:17905 denotes com
T57 518-524 UBERON:0000310 denotes breast
T58 518-531 D001943 denotes breast cancer
T59 518-531 D001943 denotes breast cancer
T61 537-541 CVCL_5552 denotes DCIS
T60 537-541 D002285 denotes DCIS
T62 537-541 D002285 denotes DCIS
T63 591-597 CVCL_E024 denotes Gemini
T67 598-607 11253 denotes vitamin D
T65 598-607 CHEBI:89324 denotes vitamin D
T66 598-607 D014807 denotes vitamin D
T68 598-607 D014807 denotes vitamin D
T69 598-607 CHEBI:27300 denotes vitamin D
T70 634-638 CVCL_D496 denotes R-21
T71 641-648 CHEBI:43176 denotes hydroxy
T75 712-727 2418 denotes cholecalciferol
T72 712-727 CHEBI:28940 denotes cholecalciferol
T73 712-727 D002762 denotes cholecalciferol
T74 712-727 D002762 denotes cholecalciferol
T76 729-736 C552206 denotes BXL0124
T77 729-736 C552206 denotes BXL0124
T78 750-759 CHEBI:35222 denotes inhibitor
T81 777-790 CVCL_5552 denotes MCF10DCIS.com
T82 782-786 D002285 denotes DCIS
T84 782-786 D002285 denotes DCIS
T86 787-790 CHEBI:17905 denotes com
T87 803-809 D009369 denotes tumors
T88 803-809 D009369 denotes tumors
T91 873-886 CVCL_5552 denotes MCF10DCIS.com
T92 878-882 D002285 denotes DCIS
T94 878-882 D002285 denotes DCIS
T96 883-886 CHEBI:17905 denotes com
T97 926-933 C552206 denotes BXL0124
T98 926-933 C552206 denotes BXL0124
T99 937-943 UBERON:0000310 denotes breast
T100 937-950 D001943 denotes breast cancer
T101 937-950 D001943 denotes breast cancer
T103 987-991 CVCL_5552 denotes DCIS
T102 987-991 D002285 denotes DCIS
T104 987-991 D002285 denotes DCIS
T105 1030-1036 D009369 denotes tumors
T106 1030-1036 D009369 denotes tumors
T107 1046-1064 CL:0000185 denotes myoepithelial cell
T108 1060-1070 UBERON:0000119 denotes cell layer
T112 1075-1092 UBERON:0005769 denotes basement membrane
T111 1075-1092 GO:0005604 denotes basement membrane
T116 1138-1151 UBERON:0001135 denotes smooth muscle
T117 1138-1151 UBERON:0000953 denotes smooth muscle
T171 1152-1157 D000199 denotes actin
T120 1152-1157 P53491 denotes actin
T121 1152-1157 P45520 denotes actin
T122 1152-1157 O00937 denotes actin
T123 1152-1157 Q05214 denotes actin
T124 1152-1157 P13363 denotes actin
T125 1152-1157 Q39596 denotes actin
T126 1152-1157 P30161 denotes actin
T127 1152-1157 P53476 denotes actin
T128 1152-1157 P51775 denotes actin
T129 1152-1157 P60011 denotes actin
T130 1152-1157 Q9P4D1 denotes actin
T131 1152-1157 P50138 denotes actin
T132 1152-1157 O65314 denotes actin
T133 1152-1157 P26183 denotes actin
T134 1152-1157 Q75D00 denotes actin
T135 1152-1157 P53502 denotes actin
T136 1152-1157 P11426 denotes actin
T137 1152-1157 P80709 denotes actin
T138 1152-1157 Q8X119 denotes actin
T139 1152-1157 Q6TCF2 denotes actin
T140 1152-1157 Q99023 denotes actin
T141 1152-1157 A5DQP9 denotes actin
T142 1152-1157 P60009 denotes actin
T143 1152-1157 O65315 denotes actin
T144 1152-1157 P26182 denotes actin
T145 1152-1157 Q9UVF3 denotes actin
T146 1152-1157 Q2U7A3 denotes actin
T147 1152-1157 Q92192 denotes actin
T148 1152-1157 Q9UVZ8 denotes actin
T149 1152-1157 P53689 denotes actin
T150 1152-1157 P68555 denotes actin
T151 1152-1157 P53455 denotes actin
T152 1152-1157 O13419 denotes actin
T153 1152-1157 P60010 denotes actin
T154 1152-1157 Q39758 denotes actin
T155 1152-1157 P81085 denotes actin
T156 1152-1157 P48465 denotes actin
T157 1152-1157 P78711 denotes actin
T158 1152-1157 P17128 denotes actin
T159 1152-1157 P91754 denotes actin
T160 1152-1157 Q24733 denotes actin
T161 1152-1157 P14235 denotes actin
T162 1152-1157 Q92193 denotes actin
T163 1152-1157 Q11212 denotes actin
T164 1152-1157 P45521 denotes actin
T165 1152-1157 P53477 denotes actin
T166 1152-1157 P53499 denotes actin
T167 1152-1157 P24902 denotes actin
T168 1152-1157 Q8SWN8 denotes actin
T169 1152-1157 O17320 denotes actin
T170 1152-1157 P10365 denotes actin
T172 1152-1157 O16808 denotes actin
T173 1152-1157 P53498 denotes actin
T174 1152-1157 Q9UVX4 denotes actin
T175 1152-1157 O81221 denotes actin
T176 1152-1157 P20904 denotes actin
T177 1152-1157 O65316 denotes actin
T178 1152-1157 O74258 denotes actin
T179 1152-1157 P53500 denotes actin
T180 1152-1157 P10989 denotes actin
T181 1152-1157 P90689 denotes actin
T183 1162-1171 C076524 denotes laminin 5
T184 1162-1171 C076524 denotes laminin 5
T185 1205-1212 C552206 denotes BXL0124
T186 1205-1212 C552206 denotes BXL0124
T187 1237-1255 CL:0000185 denotes myoepithelial cell
T188 1251-1261 UBERON:0000119 denotes cell layer
T192 1273-1290 UBERON:0005769 denotes basement membrane
T191 1273-1290 GO:0005604 denotes basement membrane
T196 1317-1324 C552206 denotes BXL0124
T197 1317-1324 C552206 denotes BXL0124
T199 1338-1347 MOP:0000569 denotes reduction
T200 1351-1356 D009369 denotes tumor
T201 1351-1356 D009369 denotes tumor
T202 1375-1382 C552206 denotes BXL0124
T203 1375-1382 C552206 denotes BXL0124
T204 1403-1421 GO:0008283 denotes cell proliferation
T205 1408-1421 UBERON:2000098 denotes proliferation
T209 1437-1446 11253 denotes vitamin D
T212 1437-1455 D018167 denotes vitamin D receptor
T213 1466-1472 D009369 denotes tumors
T214 1466-1472 D009369 denotes tumors
T215 1491-1498 C552206 denotes BXL0124
T216 1491-1498 C552206 denotes BXL0124
T219 1521-1525 SO:0000234 denotes mRNA
T217 1521-1525 D012333 denotes mRNA
T218 1521-1525 CHEBI:33699 denotes mRNA
T220 1536-1542 UBERON:0027368 denotes matrix
T221 1536-1561 D020782 denotes matrix metalloproteinases
T223 1625-1635 SO:1000009 denotes transition
T225 1681-1685 CVCL_5552 denotes DCIS
T224 1681-1685 D002285 denotes DCIS
T226 1681-1685 D002285 denotes DCIS
T227 1750-1756 CVCL_E024 denotes Gemini
T231 1757-1766 11253 denotes vitamin D
T229 1757-1766 CHEBI:89324 denotes vitamin D
T230 1757-1766 D014807 denotes vitamin D
T232 1757-1766 D014807 denotes vitamin D
T233 1757-1766 CHEBI:27300 denotes vitamin D
T234 1767-1774 C552206 denotes BXL0124
T235 1767-1774 C552206 denotes BXL0124
T236 1801-1807 UBERON:0000310 denotes breast

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 407-420 HP_0003002 denotes breast cancer
T2 407-420 HP_0100013 denotes breast cancer
T3 414-420 HP_0002664 denotes cancer
T4 518-531 HP_0003002 denotes breast cancer
T5 518-531 HP_0100013 denotes breast cancer
T6 525-531 HP_0002664 denotes cancer
T7 591-597 HP_0011091 denotes Gemini
T8 803-809 HP_0002664 denotes tumors
T9 937-950 HP_0003002 denotes breast cancer
T10 937-950 HP_0100013 denotes breast cancer
T11 944-950 HP_0002664 denotes cancer
T12 1030-1036 HP_0002664 denotes tumors
T13 1351-1356 HP_0002664 denotes tumor
T14 1466-1472 HP_0002664 denotes tumors
T15 1718-1724 HP_0002664 denotes cancer
T16 1750-1756 HP_0011091 denotes Gemini

Allie

Id Subject Object Predicate Lexical cue
SS1_24691501_1_0 116-140 expanded denotes Ductal carcinoma in situ
SS2_24691501_1_0 142-146 abbr denotes DCIS
SS1_24691501_1_1 221-246 expanded denotes invasive ductal carcinoma
SS2_24691501_1_1 248-251 abbr denotes IDC
AE1_24691501_1_0 SS1_24691501_1_0 SS2_24691501_1_0 abbreviatedTo Ductal carcinoma in situ,DCIS
AE1_24691501_1_1 SS1_24691501_1_1 SS2_24691501_1_1 abbreviatedTo invasive ductal carcinoma,IDC

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-115 DRI_Background denotes Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a Gemini vitamin D analog.
T2 116-253 DRI_Background denotes Ductal carcinoma in situ (DCIS) is a nonmalignant lesion of the breast with the potential to progress to invasive ductal carcinoma (IDC).
T3 254-421 DRI_Background denotes The disappearance and breakdown of the myoepithelial cell layer and basement membrane in DCIS have been identified as major events in the development of breast cancer.
T4 422-549 DRI_Approach denotes The MCF10DCIS.com cell line is a well-established model, which recapitulates the progression of breast cancer from DCIS to IDC.
T5 550-776 DRI_Approach denotes We have previously reported that a novel Gemini vitamin D analog, 1α,25-dihydroxy-20R-21(3-hydroxy-3-deuteromethyl-4,4,4-trideuterobutyl)-23-yne-26,27-hexafluoro-cholecalciferol (BXL0124) is a potent inhibitor of the growth of
T6 777-802 Token_Label.OUTSIDE denotes MCF10DCIS.com xenografted
T7 803-841 DRI_Approach denotes tumors without hypercalcemic toxicity.
T8 842-981 DRI_Approach denotes In this study, we utilized the MCF10DCIS.com in vivo model to assess the effects of BXL0124 on breast cancer progression from weeks 1 to 4.
T9 982-1186 DRI_Approach denotes Upon DCIS progression to IDC from weeks 3 to 4, tumors lost the myoepithelial cell layer and basement membrane as shown by immunofluorescence staining with smooth muscle actin and laminin 5, respectively.
T10 1187-1374 DRI_Background denotes Administration of BXL0124 maintained the critical myoepithelial cell layer as well as basement membrane, and animals treated with BXL0124 showed a 43% reduction in tumor volume by week 4.
T11 1375-1473 DRI_Background denotes BXL0124 treatment decreased cell proliferation and maintained vitamin D receptor levels in tumors.
T12 1474-1636 DRI_Approach denotes In addition, the BXL0124 treatment reduced the mRNA levels of matrix metalloproteinases starting at week 3, contributing to the inhibition of invasive transition.
T13 1637-1816 DRI_Outcome denotes Our results suggest that the maintenance of DCIS plays a significant role in the cancer preventive action of the Gemini vitamin D BXL0124 during the progression of breast lesions.

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 116-253 DRI_Background denotes Ductal carcinoma in situ (DCIS) is a nonmalignant lesion of the breast with the potential to progress to invasive ductal carcinoma (IDC).
T2 254-421 DRI_Background denotes The disappearance and breakdown of the myoepithelial cell layer and basement membrane in DCIS have been identified as major events in the development of breast cancer.
T3 422-549 DRI_Approach denotes The MCF10DCIS.com cell line is a well-established model, which recapitulates the progression of breast cancer from DCIS to IDC.
T4 550-776 DRI_Approach denotes We have previously reported that a novel Gemini vitamin D analog, 1α,25-dihydroxy-20R-21(3-hydroxy-3-deuteromethyl-4,4,4-trideuterobutyl)-23-yne-26,27-hexafluoro-cholecalciferol (BXL0124) is a potent inhibitor of the growth of
T5 803-841 DRI_Approach denotes tumors without hypercalcemic toxicity.
T6 842-981 DRI_Approach denotes In this study, we utilized the MCF10DCIS.com in vivo model to assess the effects of BXL0124 on breast cancer progression from weeks 1 to 4.
T7 982-1186 DRI_Approach denotes Upon DCIS progression to IDC from weeks 3 to 4, tumors lost the myoepithelial cell layer and basement membrane as shown by immunofluorescence staining with smooth muscle actin and laminin 5, respectively.
T8 1187-1374 DRI_Background denotes Administration of BXL0124 maintained the critical myoepithelial cell layer as well as basement membrane, and animals treated with BXL0124 showed a 43% reduction in tumor volume by week 4.
T9 1375-1473 DRI_Background denotes BXL0124 treatment decreased cell proliferation and maintained vitamin D receptor levels in tumors.
T10 1474-1636 DRI_Approach denotes In addition, the BXL0124 treatment reduced the mRNA levels of matrix metalloproteinases starting at week 3, contributing to the inhibition of invasive transition.
T11 1637-1816 DRI_Outcome denotes Our results suggest that the maintenance of DCIS plays a significant role in the cancer preventive action of the Gemini vitamin D BXL0124 during the progression of breast lesions.